Analgesic Treatment Mediated by Arcoxia (0663-093)

Organon

Status and phase: Completed; Phase 4

Conditions: Pain

Treatments: Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

Study type: Interventional

Funder types: Industry

Identifiers

NCT00380523

2006_034

0663-093

Details and patient eligibility

About

Allow physicians to test the efficacy of arcoxia in patients with acute pain.

Enrollment: 237 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of acute pain susceptible of pharmacological treatment
• Greater than 18 years of age
• Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion criteria

• Allergy to etoricoxib or any of its components
• Less than 18 years old
• Patient is taking anticoagulants
• Patient that already has taken any drug as analgesic

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)